Folio · SPXSet Report · Digest
v0.7.0 STABLE · 2026-11-11 · r4

2026-W46 · Nov 9–Nov 15 · Company · Profile · published

Index >>> Company >>> Profile

Veeva Systems Inc. (VEEV) — XLV Health Care · S&P 500 Profile |Veeva公司介紹

health-careS&P500xlv
SPXSet Studio
IN-HOUSE RESEARCH · 站內獨立研究

Veeva Systems Inc. (VEEV) — Business, History & S&P 500 Profile | Veeva公司介紹

Veeva Systems Inc. company profile · business segments · history · financial snapshot · S&P 500 rank #231 · Veeva公司業務歷史財務與標普500地位

中文版 ↓

PROFILE
Market data as of Oct 30, 2026 (ET) close
Financials: FY2026
MARKET CAP
$50.67B
Oct 30, 2026 close
S&P 500 WEIGHT
0.07%
Rank #231 · Oct 30, 2026
SECTOR RANK
#29
Health Care · Oct 30, 2026
S&P 500 RANK
#231
0.07% · Oct 30, 2026

SNAPSHOT

TickerVEEV
CompanyVeeva Systems Inc.
GICS sector / industryHealth Care (XLV) / Health Care Technology
S&P 500 rank (by weight)#231 · 0.07% (Oct 30, 2026)
Sector rank#29 in Health Care (Oct 30, 2026)
HeadquartersPleasanton, California
Founded2007
CEOPeter Gassner (CEO)
Employees7,928 (2026)
Market cap$50.67B (Oct 30, 2026)
Share price$312.96 (Oct 30, 2026)
SEC filingsEDGAR — CIK 0001393052

WHAT IT DOES

Veeva Systems Inc., headquartered in Pleasanton, California, provides cloud software, data and consulting built only for the life sciences industry — pharmaceutical, biotechnology and medical-device companies, plus the contract research and sales organisations that serve them. It reported 1,552 customers in its fiscal 2026 annual report.

Its one-line model: sell industry-specific subscription software that manages drug development and drug selling — clinical trials, regulatory submissions, quality, safety and commercial CRM — and charge for the implementation and consulting that embeds it. Subscriptions were $2,684.2M of fiscal 2026 revenue, 84% of the total.

The economics are vertical-SaaS economics: one validated product release serves every customer, regulated records are costly to move, and land-and-expand across its four clouds lifts revenue per customer. Fiscal 2026 total revenues were $3,195.3M, up 16% year over year, with GAAP operating income of $916.4M.

BUSINESS SEGMENTS

R&D Solutions — Veeva Development CloudClinical, regulatory and safety application suites on the Veeva Vault platform (EDC, eTMF, CTMS, RTSM, RIM, Safety) — R&D Solutions together produced about 55% of fiscal 2026 total revenue.
R&D Solutions — Veeva Quality CloudQuality management, regulated documents, training and laboratory applications (QMS, QualityDocs) for manufacturing and product-release compliance.
Commercial Solutions — Veeva Commercial CloudVault CRM, content, medical and engagement applications for sales, marketing and medical teams — Commercial Solutions produced about 45% of fiscal 2026 total revenue; its subscription revenue was $1,258M.
Veeva Data CloudReference, deep, transaction and patient data and analytics (including Crossix) feeding commercial decisions across the other clouds.
Professional Services & Business ConsultingImplementation, configuration, managed services and consulting — fiscal 2026 professional services and other revenue of $511.1M, 16% of total revenue.

R&D Solutions — Veeva Development Cloud Clinical, regulatory and safety application suites on the Veeva Vault platform (EDC, eTMF, CTMS, RTSM, RIM, Safety) — R&D Solutions together produced about 55% of fiscal 2026 total revenue.

R&D Solutions — Veeva Quality Cloud Quality management, regulated documents, training and laboratory applications (QMS, QualityDocs) for manufacturing and product-release compliance.

Commercial Solutions — Veeva Commercial Cloud Vault CRM, content, medical and engagement applications for sales, marketing and medical teams — Commercial Solutions produced about 45% of fiscal 2026 total revenue; its subscription revenue was $1,258M.

Veeva Data Cloud Reference, deep, transaction and patient data and analytics (including Crossix) feeding commercial decisions across the other clouds.

Professional Services & Business Consulting Implementation, configuration, managed services and consulting — fiscal 2026 professional services and other revenue of $511.1M, 16% of total revenue.

HISTORY

YearMilestone
2007Veeva is founded in 2007 by Peter Gassner and Matt Wallach, on the thesis that life sciences needs purpose-built industry cloud software; its first product is a pharma CRM built on the Salesforce platform Gassner had helped build.
2011Veeva introduces Veeva Vault in 2011, its own platform for regulated content and data management — the move that takes it beyond CRM into R&D.
2013Veeva lists on the New York Stock Exchange in October 2013, one of the most successful software IPOs of its era.
2019Veeva acquires Crossix, a privacy-safe patient data and analytics company, and Physicians World, a business-process outsourcing provider, in late 2019 — the data and services build-out behind Data Cloud.
2021In February 2021 Veeva becomes the first publicly traded company to convert to a public benefit corporation.
2025Veeva ends its partnership with Salesforce in 2025 as its CRM completes the migration to its own Vault platform, removing its original platform dependency.

COMPETITIVE POSITION

  • Vertical depth: software built only for life sciences regulation — validation, audit trails and submission workflows that generalist platforms do not ship — across 1,552 customers including most top-20 drug makers named in its annual report (Bayer, Boehringer Ingelheim, Eli Lilly, Gilead, Merck & Co., Novartis).
  • Switching costs: regulated documents carry their approval history, so leaving means migrating records and revalidating the replacement while regulated work continues.
  • Recurring base: 84% of fiscal 2026 revenue was subscription revenue, growing 17% year over year.
  • Competition set: Salesforce and IQVIA in commercial and data, Oracle and Dassault's Medidata in clinical and R&D systems.

FINANCIAL SNAPSHOT

Total revenues$3,195.3M (FY2026, year ended Jan 31, 2026)
Operating income$916.4M (FY2026 operating income)
Net income$908.9M (FY2026 net income)
Diluted EPS$5.44 (FY2026 diluted EPS)
Source: Veeva fiscal 2026 results release (March 4, 2026) and fiscal 2026 Form 10-K (year ended January 31, 2026) — total and subscription revenues, operating and net income via the release and Wikipedia company profile; product-area subscription splits and diluted EPS via StockAnalysis / 10-K reporting. Veeva's fiscal year ends January 31, so FY2026 is the year ended January 31, 2026. Non-GAAP operating income was $1,433.8M.

KEY RISKS

  • Customer concentration in large pharma: a small number of global drug makers drive a large share of revenue and product decisions.
  • Platform transition: the Vault CRM migration off Salesforce must complete without churn to Salesforce's own life-sciences push.
  • Regulatory change: validation and data rules in the U.S., Europe and China shape both demand and product cost.
  • Growth deceleration: revenue growth has stepped down from earlier rates as the CRM base matured; new clouds (Data, AI agents) must carry expansion.
  • Stock-based compensation: $472.7M in fiscal 2026, the main gap between GAAP and non-GAAP profit.

WHY IT MATTERS FOR THE S&P 500

Veeva is a small-weight health-care constituent: rank #231 by weight at 0.07% as of Oct 30, 2026, and #29 in Health Care. As the index's pure-play life-sciences software company, it is the cleanest read on how drug makers digitise development and commercialisation — and on the durability of vertical SaaS pricing.

SOURCES & METHODOLOGY

Financials, segments, headquartersVeeva fiscal 2026 results release and Form 10-K data via company release, Wikipedia company profile and StockAnalysis (year ended January 31, 2026); headquarters, CEO and employees via Wikipedia company profile
Index weight & ranksSlickcharts S&P 500 weights, Oct 30, 2026 close, fetched Nov 2, 2026 (dispatch baseline, used verbatim)
Market cap$50.67B (Oct 30, 2026)
LogoSPXSet logo library, compiled from company official websites, filings, or Wikipedia; as company logos are dynamic corporate information, no 100% guarantee is made for the graphics.
ChartSPXSet chart library, monthly bars, compiled from Yahoo public information.

Price Chart — 10-Year Monthly Candles

VEEV

Source: Yahoo Finance monthly bars, split-adjusted · Data as of Sep 30, 2026 (last closed month) · SPXSet.com

FINANCIALS

繁體中文版

公司快照

股票代號VEEV
公司Veeva Systems Inc.(Veeva)
GICS 板塊/行業醫療保健(XLV)/醫療保健科技
標普500排名(按權重)#231 · 0.07%(Oct 30, 2026)
板塊內排名醫療保健 #29(Oct 30, 2026)
總部美國加利福尼亞州普萊森頓
成立2007年
執行長Peter Gassner(執行長)
員工7,928(2026年)
市值$50.67B(Oct 30, 2026)
股價$312.96(Oct 30, 2026)
SEC 申報EDGAR — CIK 0001393052

業務概覽

Veeva 總部位於加利福尼亞州普萊森頓,專為生命科學行業——製藥、生物科技與醫療器械公司,以及其外判研究與銷售機構——提供雲端軟件、數據與諮詢服務。公司 2026 財年年報披露客戶數為 1,552 家。

其一句話商業模式是:銷售專為行業而設的訂閱軟件,管理藥物研發與藥物銷售——臨床試驗、監管申報、品質、安全與商業 CRM——並就嵌入系統的實施與諮詢收費。訂閱收入 26.842 億美元,佔 2026 財年總收入的 84%。

其經濟學是垂直 SaaS 的經濟學:一套經驗證的產品版本服務所有客戶,受監管紀錄遷移成本高昂,而四大雲之間的交叉銷售提升每名客戶的收入。2026 財年總收入 31.953 億美元,按年增長 16%,GAAP 營業利潤 9.164 億美元。

業務板塊

研發解決方案 — Veeva Development Cloud建於 Veeva Vault 平台的臨床、監管與安全應用套件(EDC、eTMF、CTMS、RTSM、RIM、Safety)——研發解決方案合計約佔 2026 財年總收入的 55%。
研發解決方案 — Veeva Quality Cloud品質管理、受監管文件、培訓與實驗室應用(QMS、QualityDocs),支援生產與產品放行合規。
商業解決方案 — Veeva Commercial Cloud供銷售、市場與醫學團隊使用的 Vault CRM、內容、醫學與互動應用——商業解決方案約佔 2026 財年總收入的 45%,其訂閱收入為 12.58 億美元。
Veeva Data Cloud參考、深度、交易與患者數據及分析(包括 Crossix),為其他雲的商業決策提供數據基礎。
專業服務與商業諮詢實施、配置、託管服務與諮詢——2026 財年專業服務及其他收入 5.111 億美元,佔總收入 16%。

研發解決方案 — Veeva Development Cloud 建於 Veeva Vault 平台的臨床、監管與安全應用套件(EDC、eTMF、CTMS、RTSM、RIM、Safety)——研發解決方案合計約佔 2026 財年總收入的 55%。

研發解決方案 — Veeva Quality Cloud 品質管理、受監管文件、培訓與實驗室應用(QMS、QualityDocs),支援生產與產品放行合規。

商業解決方案 — Veeva Commercial Cloud 供銷售、市場與醫學團隊使用的 Vault CRM、內容、醫學與互動應用——商業解決方案約佔 2026 財年總收入的 45%,其訂閱收入為 12.58 億美元。

Veeva Data Cloud 參考、深度、交易與患者數據及分析(包括 Crossix),為其他雲的商業決策提供數據基礎。

專業服務與商業諮詢 實施、配置、託管服務與諮詢——2026 財年專業服務及其他收入 5.111 億美元,佔總收入 16%。

歷史沿革

年份里程碑
2007Veeva 於 2007 年由 Peter Gassner 與 Matt Wallach 創立,主張生命科學需要專門的行業雲軟件;首個產品是建於 Gassner 曾參與開發的 Salesforce 平台上的製藥 CRM。
2011Veeva 於 2011 年推出 Veeva Vault——自家的受監管內容與數據管理平台——由此走出 CRM、進入研發領域。
2013Veeva 於 2013 年 10 月在紐約證券交易所上市,是其年代最成功的軟件 IPO 之一。
2019Veeva 於 2019 年底收購隱私安全患者數據與分析公司 Crossix 及業務流程外判商 Physicians World,構成 Data Cloud 背後的數據與服務佈局。
20212021 年 2 月,Veeva 成為首家轉為公益公司(public benefit corporation)的上市公司。
2025Veeva 於 2025 年結束與 Salesforce 的合作,其 CRM 完成向自家 Vault 平台的遷移,消除原有的平台依賴。

競爭地位

  • 垂直深度:只為生命科學監管而建的軟件——驗證、審計追蹤與申報流程是通用平台所不提供的——客戶 1,552 家,包括其年報點名的大多數前二十大藥企(Bayer、Boehringer Ingelheim、Eli Lilly、Gilead、Merck & Co.、Novartis)。
  • 轉換成本:受監管文件附帶其審批歷史,離開意味著遷移紀錄並在監管工作持續進行下重新驗證替代系統。
  • 經常性基礎:2026 財年收入的 84% 為訂閱收入,按年增長 17%。
  • 競爭集合:商業與數據領域的 Salesforce 與 IQVIA,臨床與研發系統領域的 Oracle 與 Dassault 旗下 Medidata。

財務快照

總收入$3,195.3M(FY2026,截至 2026 年 1 月 31 日)
營業利潤$916.4M(FY2026 營業利潤)
淨利潤$908.9M(FY2026 淨利潤)
稀釋 EPS$5.44(FY2026 稀釋 EPS)
來源:Veeva 2026 財年業績公告(2026 年 3 月 4 日)及 2026 財年 Form 10-K(截至 2026 年 1 月 31 日)——總收入、訂閱收入、營業利潤與淨利潤經公司公告與維基百科公司資料;產品領域訂閱拆分與稀釋 EPS 經 StockAnalysis/10-K 報道。Veeva 財年於 1 月 31 日結束,故 FY2026 指截至 2026 年 1 月 31 日止年度。非 GAAP 營業利潤為 14.338 億美元。

主要風險

  • 大藥企客戶集中:少數全球藥企佔收入與產品決策的很大比重。
  • 平台過渡:Vault CRM 脫離 Salesforce 的遷移必須完成,同時避免客戶流向 Salesforce 自家的生命科學攻勢。
  • 監管變化:美國、歐洲與中國的驗證與數據規則同時塑造需求與產品成本。
  • 增長放緩:CRM 基礎成熟後收入增速已回落,新增長須由新雲(Data、AI 代理)承載。
  • 股份薪酬:2026 財年 4.727 億美元,是 GAAP 與非 GAAP 利潤差距的主要來源。

對標普500的重要性

Veeva 是權重較小的醫療保健成分股:按權重排名 #231,權重 0.07%(以 Oct 30, 2026 為準),醫療保健板塊內排名 #29。作為指數中純粹的生命科學軟件公司,它是觀察藥企如何把研發與商業化數碼化、以及垂直 SaaS 定價耐久性的最清晰指標。

來源與方法

財務、板塊、總部Veeva 2026 財年業績公告與 Form 10-K 數據,經公司公告、維基百科公司資料與 StockAnalysis(截至 2026 年 1 月 31 日);總部、執行長與員工經維基百科公司資料
指數權重與排名Slickcharts S&P 500 權重,Oct 30, 2026 收盤,Nov 2, 2026 抓取(派工基線,原文引用)
市值$50.67B(Oct 30, 2026)
LogoSPXSet logo 庫,整理自企業官方網站、文件或維基百科;由於是企業自身動態資訊,不對圖形做百分百保證。
股價圖SPXSet 圖表庫月線,整理自 Yahoo 公開資訊。

10年股價K線圖(月K)

VEEV

來源:Yahoo Finance 月線(經拆股調整)· 數據截至 2026 年 9 月 30 日(最後已收月份)· SPXSet.com

財報

SPXSet Studio

SPXSet in-house research — market structure, options and volatility. Not investment advice.
SPXSet 站內獨立研究,聚焦 SPX 市場結構、期權與波動率;內容不構成投資建議。

SPXSet · Company Library · VEEV
Data as of Oct 30, 2026 · Financials FY2026 (10-K) · Market data Oct 2026
Previous · Humana Inc. (HUM) — XLV Health Care · S&P 500 Profile |Humana公司介紹Next · AutoZone, Inc. (AZO) — XLY Consumer Discretionary · S&P 500 Profile |AutoZone公司介紹

Entered 2026-11-01 19:26 · updated 2026-11-15 00:12 · rev 5